Sanofi faces Lemtrada lawsuit; Merck gets into the weight-management business;

@FierceBiotech: The 5 biggest trends in biopharma R&D in 2013. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: J&J partners up with Orion on a new approach to fighting Alzheimer's--neurotransmitters--a la Lundbeck/Otsuka. News | Follow @JohnCFierce

@DamianFierce: Welcome back, Iclusig. Release | Follow @DamianFierce

@EmilyMFierce: Cells from the eye are inkjet-printed for the first time. More | Follow @EmilyMFierce

> Investors are suing Sanofi ($SNY) on claims the company misled the public about the safety and efficacy of Lemtrada, a multiple sclerosis drug awaiting FDA approval. Article

> Osiris Therapeutics ($OSIR) picked up a final $15 million payment from Mesoblast tied to its sale of the Prochymal. Release

> Merck ($MRK) is getting into the service-based weight-management business, kicking off a new segment targeting employers, hospitals, medical groups and health plans. More

Medical Device News

@FierceMedDev: Baxter nails a CE mark for next-generation home hemodialysis. More | Follow @FierceMedDev

@MarkHFierce: More problems for 23andMe--two women are suing the company over its test claims. Article | Follow @MarkHFierce

@MichaelGFierce: 'Walking' DNA motor on nanotube tracks could someday deliver drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: FDA approves Philips' spectrometry for dense breasts in cancer screenings. Story | Follow @GalenMoore

> IPOs, M&A and the Supreme Court filled out a heady year for med tech. Editor's Corner

> Vermillion secures $17.6M to expand push for ovarian cancer Dx. News

> AtriCure grabs ablation device maker Estech for $34M. More

Pharma News

@FiercePharma: Top new news Thursday: Bristol bails out of diabetes venture in $4.1B sell-out to AstraZeneca. More | Follow @FiercePharma

@EricPFierce: FDA still has to approve J&J plans to lease part of Ben Venue plant and make Doxil itself. Article | Follow @EricPFierce

@CarlyHFierce: Bad news for AstraZeneca. Appeals court frees Hanmi of double-damage risk for its Nexium copy. Story | Follow @CarlyHFierce

> Actelion will pay $407M in damages for its buyout to protect Tracleer. News

> Jazz will pay $1B for Italy's Gentium, sweeping up another specialty drugmaker. Story

> Doxil update: J&J strikes deal to manufacture Doxil itself at Ben Venue plant. More

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.